Rhumbline Advisers Decreases Stock Position in Certara, Inc. (NASDAQ:CERT)

Rhumbline Advisers decreased its position in shares of Certara, Inc. (NASDAQ:CERT) by 8.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 259,690 shares of the company’s stock after selling 22,799 shares during the period. Rhumbline Advisers owned approximately 0.16% of Certara worth $3,597,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. purchased a new position in shares of Certara in the 2nd quarter worth $26,000. Pineridge Advisors LLC bought a new position in shares of Certara in the 4th quarter valued at about $28,000. Innealta Capital LLC purchased a new position in Certara in the second quarter worth about $36,000. YHB Investment Advisors Inc. bought a new stake in Certara during the first quarter worth approximately $47,000. Finally, SG Americas Securities LLC purchased a new stake in Certara during the second quarter valued at approximately $226,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.39% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CERT shares. JMP Securities reissued a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. UBS Group reduced their target price on shares of Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Barclays dropped their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Robert W. Baird reduced their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, KeyCorp dropped their target price on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Certara presently has an average rating of “Hold” and an average price target of $17.79.

Certara Stock Up 1.2 %

Shares of NASDAQ:CERT opened at $10.83 on Wednesday. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.74 billion, a P/E ratio of -27.77, a price-to-earnings-growth ratio of 5.23 and a beta of 1.49. The business’s 50 day moving average is $13.48 and its 200 day moving average is $15.51. Certara, Inc. has a 52-week low of $10.35 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. During the same quarter in the previous year, the company posted $0.10 EPS. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. Sell-side analysts predict that Certara, Inc. will post 0.27 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.